Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates
Shots:
- Sunovion to receive $270M up front- $620M as development milestone for 4 candidates & is also eligible to receive sales milestone. Sunovion & Otsuka will share profits & expenses for clinical studies- applications for approval- & commercialization in each licensed territories
- Otsuka gets the rights from Sunovion to jointly develop & commercialize 4 compounds globally i.e.- ulotaront (SEP-363856)- SEP-4199- SEP-378614 & SEP-380135 to treat neuropsychiatric disorders
- Sumitomo Dainippon Pharma & Otsuka plan to co-promote 4 candidates jointly where Sumitomo Dainippon will record sales in the US- Canada- Japan & Asia. Otsuka will record sales in 41 other countries and regions including the EU
| Ref: Otsuka | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com